OBJECTIVES: The beta-lactamases with extended spectrum of activity (ESBL) are medically one of the most important group of enzymes. Another group of beta-lactamases representing of Enterobacteriaceae is group of the AmpC-type cephalosporinases. The presented study provides identification and determination of the spectrum of resistance against different and clinically used antimicrobial drugs in the clinical isolates of Escherichia coli. METHODS: These isolates had origin in different departments of the L. Pasteur University Hospital in Košice. The goal was the detection of beta-lactamase production with extended-spectrum effect and testing of AmpC-type cephalosporinases by several phenotypic tests in clinical isolates. MALDI-TOF MS analysis was performed on a Microflex MALDI Biotyper. Samples were positively tested for ESBL with the use of the disc diffusion method. PCR were performed with a series of primers designed for the detection of Ambler class A, B and C beta-lactamase genes. RESULTS: For all 485 isolates, we determined the production of ESBL, which we detected in 166 E. coli isolates, which represents a 34.2% prevalence of ESBL production. It is clear from the results that the prevalence of ESBL-producing E. coli out of the total number of E. coli investigated reached 34.2%. In the monitored period, we confirmed at least one resistance gene from 485 E. coli in 188 positive isolates. CONCLUSIONS: We describe a complex ESBL epidemiology. The study revealed a high rate of ESBL-producing E. coli isolates; blaTEM and blaSHV enzymes dominated in ESBL-positive E. coli isolates in the L. Pasteur University Hospital in Košice.

Department of Medical and Clinical Microbiology Faculty of Medicine Pavol Jozef Safarik University in Kosice Kosice Slovak Republic

Department of Midwifery Faculty of Health Care University of Presov Presov Slovak Republic

Department of Public Health and Hygiene Faculty of Medicine Pavol Jozef Safarik University in Kosice Kosice Slovak Republic

Zobrazit více v PubMed

Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence. 2012;3(5):421-33. PubMed

Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents. 2012;39(4):283-94. PubMed

Khan HA, Baig FK, Mehboob R. Nosocomial infections: epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed. 2017;7(5):478-82.

Falagas ME, Karageorgopoulos DE. Extended-spectrum β-lactamase-producing organisms. J Hosp Infect. 2009;73(4):345-54. PubMed

Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended spectrum β-lactamases: types, epidemiology and treatment. Saudi J Biol Sci. 2015;22(1):90-101.

Kargar M, Kargar M, Jahromi MZ, Najafi A, Ghorbani-Dalini S. Molecular detection of ESBLs production and antibiotic resistance patterns in Gram negative bacilli isolated from urinary tract infections. Indian J Pathol Microbiol. 2014 Apr-Jun;57(2):244-8.

Colello R, Etcheverría AI, Di Conza JA, Gutkind GO, Padola NL. Antibiotic resistance and integrons in Shiga toxin-producing Escherichia coli (STEC). Braz J Microbiol. 2015 Mar 1;46(1):1-5.

Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control. 2007;35(9):606-12.

Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004 Jan;48(1):1-14.

Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al.; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011.

Papagiannitsis CC, Dolejska M, Izdebski R, Giakkoupi P, Skálová A, Chudějová K, et al. Characterisation of IncA/C2 plasmids carrying an In416-like integron with the blaVIM-19 gene from Klebsiella pneumoniae ST383 of Greek origin. Int J Antimicrob Agents. 2016 Feb;47(2):158-62. PubMed

Frimodt-Moller N. Mecillinam - reversion of resistance and how to test it. EBioMedicine. 2017 Sep;23:4-5. PubMed

Beneš J. Antibiotics: systematics, properties, use. Prague: Grada; 2018. (In Czech.)

Freiwald A, Sauer S. Phylogenetic classification and identification of bacteria by mass spectrometry. Nat Protoc. 2009;4(5):732-42. PubMed

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. CLSI document M100-S20. Wayne (PA): CLSI; 2010.

EUCAST. Disk diffusion method, antibiotic susceptibility testing, version 7.0 [Internet]. EUCAST [cited 2019 Jul 19]. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3.xls.

Thakuria B, Lahon K. The beta lactam antibiotics as an empirical therapy in a developing country: an update on their current status and recommendations to counter the resistance against them. J Clin Diagn Res. 2013 Jun;7(6):1207-14. PubMed

Rodríguez-Bano J, Miró E, Villar M, Coelho A, Gozalo M, Borrell N, et al. Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect. 2012;64(2):176-83. PubMed

Gude MJ, Seral C, Sáenz Y, Cebollada R, González-Domínguez M, Torres C, et al. Molecular epidemiology, resistance profiles and clinical features in clinical plasmid-mediated AmpC-producing Enterobacteriaceae. Int J Med Microbiol. 2013;303(8):553-7.

Miró E, Agüero J, Larrosa MN, Fernández A, Conejo MC, Bou G, et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis. 2013;32(2):253-9.

Reuland EA, Hays JP, de Jongh DM, Abdelrehim E, Willemsen I, Kluytmans JA, et al. Detection and occurrence of plasmid-mediated AmpC in highly resistant gram-negative rods. PLoS One. 2014 Mar 18;9(3):e91396. doi: 10.1371/journal.pone.0091396. PubMed DOI

Thirapanmethee K. Extended spectrum β-lactamases: critical tools of bacterial resistance. Mahidol Univ J Pharm Sci. 2012;39(1):1-8.

Abdallah HM, Wintermans BB, Reuland EA, Koek A, al Naiemi N, Ammar AM, et al. Extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae isolated from Egyptian patients with suspected blood stream infection. PLoS One. 2015;10(5):e0128120. doi: 10.1371/journal.pone.0128120. PubMed DOI

Mukherjee M, Basu S, Mukherjee SK, Majumder M. Multidrug-resistance and extended spectrum beta-lactamase production in uropathogenic E. coli which were isolated from hospitalized patients in Kolkata, India. J Clin Diagn Res. 2013;7(3):449-53.

Lovayová V, Vargová L, Nagyová M, Dudriková E, Dorko E, Siegfried L. Extended -spectrum β-lactamases producing Escherichia coli strains monitored over 4 years in the university hospital in Kosice, Slovakia. Curr Res Microbiol. 2016;7(1):32-8.

Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43(1):52-9. PubMed

Kassakian SZ, Mermel LA. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. Antimicrob Resist Infect Control. 2014 Mar 25;3(1):9. doi: 10.1186/2047-2994-3-9. PubMed DOI

Søraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing Enterobacteriaceae - a case-control study in a low prevalence country. PLoS One. 2013 Jul 23;8(7):e69581. doi: 10.1371/journal.pone.0069581. PubMed DOI

Ogbolu DO, Daini OA, Ogunledun A, Alli AO, Webber MA. High levels of multidrug resistance in clinical isolates of Gram-negative pathogens from Nigeria. Int J Antimicrob Agents. 2011;37(1):62-6. PubMed

Koksal I, Yilmaz G, Unal S, Zarakolu P, Korten V, Mulazimoglu L, et al. Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections. J Antimicrob Chemother. 2017 May 1;72(5):1364-72. PubMed

Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008 Sep 22;168(17):1897-902.

Park YS, Bae IK, Kim J, Jeong SH, Hwang SS, Seo YH, et al. Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia. Yonsei Med J. 2014 Mar;55(2):467-75. PubMed

Cohen Stuart J, Dierikx C, Al Naiemi N, Karczmarek A, Van Hoek AHAM, Vos P, et al. Rapid detection of TEM, SHV and CTX-M extended-spectrum β-lactamases in Enterobacteriaceae using ligation-mediated amplification with microarray analysis. J Antimicrob Chemother. 2010;65(7):1377-81. PubMed

Sheng WH, Badal RE, Hsueh PR, SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981-8.